1011460-56-2

Basic information

• Product Name: N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE
• Synonyms: N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE;1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID METHOXYMETHYL-AMIDE;N-methoxy-N-methyl-1-(trifluoromethyl)cyclopropanecarboxamide
• CAS NO: 1011460-56-2
• Molecular Formula: C₇H₁₀F₃NO₂
• Molecular Weight: 197.1550096
• Mol File: 1011460-56-2.mol

Chemical Properties

• Boiling Point: 155.3±43.0 °C(Predicted)
• Appearance: /
• Density: 1.349±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE(1011460-56-2)
• EPA Substance Registry System: N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE(1011460-56-2)

Safety Data

• Hazardous Substances Data: 1011460-56-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE is utilized as a potential candidate in pharmaceutical research and drug development due to its unique structure and properties. It may exhibit biological activity and pharmacological effects that could be beneficial for treating specific medical conditions.
Used as an Intermediate in Organic Synthesis:
In the field of organic chemistry, N-METHOXYMETHYL-1-TRIFLUOROMETHYL-CYCLOPROPANECARBOXYLIC ACID AMIDE serves as a valuable intermediate compound for the synthesis of other organic compounds, contributing to the development of new chemical entities and materials.

Upstream product

• 277756-46-4 1-(trifluoromethyl)cyclopropanecarboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1011460-55-1 (4-chloro-2-methylphenyl)(1-(trifluoromethyl)cyclopropyl)methanone 
• 1022154-58-0 (2-methyl-1-trityl-1H-imidazol-4-yl)-(1-trifluoromethyl-cyclopropyl)-methanone 
• 1021736-30-0 2-methyl-4-{[1-(trifluoromethyl)cyclopropyl]methyl}-1-trityl-1H-imidazole 
• 1022152-92-6 2-[4-(1H-pyrazol-1-yl)phenyl]-1-(4-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-imidazol-2-yl)propan-2-ol 
• 1022155-26-5 C₃₉H₃₂F₆N₄O 
• 1229311-61-8 1-(trifluoromethyl)cyclopropane-1-carbaldehyde 
• 1400701-77-0 (4-bromophenyl)[1-(trifluoromethyl)cyclopropyl]methanone 
• 1400701-80-5 methyl 4-{[1-(trifluoromethyl)cyclopropyl]methyl}benzoate 
• 1400701-76-9 (4-{[1-(trifluoromethyl)cyclopropyl]methyl}phenyl)methanol 
• 1423304-33-9 6-benzyl-2-(1-(trifluoromethyl)cyclopropyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 

Relevant articles and documents

Lead Optimization toward Proof-of-Concept Tools for Huntington's Disease within a 4-(1 H -Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole. (Chemical Presented)

KCNQ Potentiators

Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.

BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection

Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure-activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

A concise one-pot synthesis of trifluoromethyl-containing 2,6-disubstituted 5,6,7,8-tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines

5,6,7,8-Tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines with appended trifluoromethyl groups are valuable chemotypes in medicinal chemistry due to the presence of a partially-saturated bicyclic ring and metabolically-stable CF3 group. 1H NMR studies were used to optimize the preparation of such compounds, using a three-step/one-pot procedure, to provide novel 2,6-disubstitued derivatives with a tertiary-substituent. Racemic 2,6-disubstituted tetrahydroquinolines were separated by chiral HPLC to provide single enantiomers.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.